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To the Editor: 
The enclosed manuscript Leptin induces the generation of procoagulant, tissue factor 
bearing microparticles by human peripheral blood mononuclear cells that we would like to 
submit to BBA general interest for possible publication represents original work. It has not 
been published before, except in abstract form, and is currently not under evaluation by 
other Journals. 
The manuscript describes a novel mechanism that potentially links the adipokine, leptin, to 
cardiovascular and thrombotic disorders in obese individuals. The mechanism involves the 
generation of procoagulant, tissue factor-bearing vesicles, upon incubation of 
mononuclear cells with leptin via intracellular calcium mobilization and ERK1/2 activation. 
We therefore deem the manuscript, if considered scientifically sound, to be of general 
interest. 
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Abstract 
Background: Obesity is linked to increased thrombotic risk. Circulating leptin 
concentration correlates with body mass index. Microparticles are small (.05-1 
µm) vesicles shed by activated and apoptotic cells, involved in numerous 
pathophysiologically relevant phenomena including blood coagulation and 
thrombosis. We tested the hypothesis that leptin induces the shedding of 
procoagulant, tissue factor bearing microparticles by human peripheral blood 
mononuclear cells, and investigated the intracellular mechanisms leading to 
microparticle release upon incubation with leptin. 
Methods: Peripheral blood mononuclear cells were isolated from healthy 
donors. Cells were incubated with leptin in the presence or in the absence of a 
phospholipase C inhibitor, U73122, a calmodulin inhibitor, W-7, and  three 
inhibitors of mitogen activated protein kinases. Microparticle generation was 
assessed as phosphatidylserine concentration with a prothrombinase assay and 
by cytofluorimetric analysis. Tissue factor expression on microparticles was 
measured with a one-stage clotting assay. Intracellular calcium concentration 
was assessed by a fluorescent probe.  
Results: Leptin increased intracellular calcium mobilization and stimulated the 
generation of tissue factor-bearing MP by peripheral blood mononuclear cells, 
as assessed by phosphatidylserine quantification, clotting tests and flow-
cytometry. U73122, PD98059 (an extracellular signal-regulated kinase1/2 
inhibitor), and W-7, significantly inhibited leptin-induced MP release. SB203580 
(a p38 inhibitor), and SP600125 (a c-JunN-terminal kinase inhibitor) had no 
effect.  
Conclusion: Leptin induced generation of procoagulant microparticles might 
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represent a link between obesity and atherothrombotic risk. Inhibition of leptin-
induced microparticle generation might prove a viable strategy for the reduction 
of such risk in obese individuals. 
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1 Introduction 
Obesity is a risk factor for vascular disorders, including hypertension, coronary 
artery diseases and thrombosis [1, 2]. The secretory products of adipose tissue 
contribute to the elevated risk of cardiovascular disease with mechanisms that 
are complex and partially unknown [3]. Leptin is a 16 kDa non-glycosylated 
polypeptide product of the ob gene and is mainly produced and secreted by fat 
cells in proportion to fat mass to signal the repletion of body energy stores to 
the hypothalamus [4]. Besides its role in regulating the body’s energy balance, 
however, leptin is also involved in a variety of other biologically relevant 
phenomena, including the upregulation of the synthesis of interleukin-18 in 
monocytes [5], of Vascular Cell Adhesion Molecule-1 in mouse chondrocytes 
[6], of matrix metalloproteinases in cartilage [7] and of the initiator of the 
extrinsic pathway of blood coagulation, tissue factor (TF), in monocytes [8, 9] 
and neutrophils [10].  
Microparticles (MP) are small membrane vesicles (0.05 - 1 μm) shed from cells 
following activation or during injury and apoptosis [11]. Long considered inert 
debris, MP are in fact involved in a number of physiologically relevant 
responses, including cell-cell communication [12], inflammation [13] and blood 
coagulation [14, 15]. The mechanisms leading to the generation of MP are only 
partially known; however, two distinct cellular processes have been 
characterized: chemical and physical cell activation, induced through an 
increase in intracellular calcium concentration by agonists or shear stress, 
respectively, and apoptosis, induced both by deprivation of growth factors or by 
apoptotic inducers [11, 16, 17]. MP express on their outer leaflet the negatively 
charged phospholipid, phosphatidylserine (PS), which represents an ideal 
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surface for the assembly of prothrombinase and tenase, the enzymatic 
complexes responsible for the activation of coagulation factors II and X, 
respectively [18]. Furthermore, the procoagulant potential of mononuclear cell-
derived MP can be increased by the expression of TF [19]. In fact, the so called 
blood-borne TF [20] is probably, at least in part, TF bound to MP [14]. Several 
studies have shown that circulating MP are increased in most cardiovascular 
diseases and in patients with cardiovascular risk factors [21-23]. In obese and 
overweight subjects, an increased number of circulating MP has also been 
reported [24-26].  
We investigated whether leptin induces the shedding of procoagulant, TF-
bearing MP by human peripheral blood mononuclear cells (PBMC), thus lending 
further support to the hypothesis that these structures are, at least in part, 
responsible for the increased thrombotic risk in obese patients.  
 
2 Materials and methods 
2.1 Reagents and kits 
Leptin, U73122, SP600125, SB203580, W-7, RPMI 1640 medium, penicillin, 
streptomycin, L-glutamine, fetal bovine serum, trypan blue, phosphate buffered 
saline (PBS), Ficoll-Hystopaque, dextran, (3-(4,5-dimethylthiazol-2-yl)- 2,5-
diphenyltetrazolium bromide) (MTT), were obtained from Sigma (Milan, Italy). 
The absence of lypopolysaccharide in leptin powder was attested by Sigma 
(Milan, Italy). Thromboplastin standard was obtained from Beckman Coulter 
(Milano, Italy). Human anti-TF antibody was obtained from America Diagnostica 
(Instrumentation Laboratory, Milano, Italy). PD98059 was obtained from 
Cayman Chemical (Ann Arbor, MI, USA). The Zymuphen MP-Activity kit was 
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obtained from Hyphen BioMed (Neuville-sur-Oise, France). The Fluo-4 NW 
Calcium Assay kit was obtained from Molecular Probes (Invitrogen, Milan, Italy). 
Annexin V-fluoresceinisothyocianate (FITC), Annexin V-allophycocyanin (APC) 
and  PE-labeled mouse anti human CD14 antibody was purchased from BD 
Bioscience (San Jose, CA, USA). Phycoerythrin (PE)-labeled propidium iodide 
was purchased from Immunological Science (Rome, Italy). Carboxyfluorescein 
diacetate succinimidyl ester (CFSE)-fluoresceinisothyocianate (FITC) was 
purchased from Miltenyi Biotec (Calderara di Reno, Italy). Megamix™, a blend 
of monodisperse fluorescent beads of three diameters (.5, .9 and 3.0 μm), was 
purchased from BioCytex (Marseille, France).  
2.2 PBMC isolation and culture 
PBMC were isolated either from fresh buffy coats obtained from the local blood 
bank or from the peripheral blood of normal volunteers exactly as described 
[27]. The procedure was approved by the local ethics committee in accordance 
with the Declaration of Helsinki. Due to the strictly blind nature of the procedure, 
we were not informed whether some of the blood bank donors were taking 
medications or had some abnormal laboratory data; in contrast, the normal 
volunteers were recruited among the laboratory personnel and they had no 
relevant abnormalities that we are aware of. Briefly, a fresh buffy coat was 
mixed gently with an equal volume of 2,5% Dextran T500, and left for 40 
minutes for erythrocyte sedimentation. Ten mL of leukocyte-rich supernatant 
was layered over 5 mL of Ficoll-Hystopaque and centrifuged for 30 minutes at 
350 x g at 4°C. The PBMC-rich ring was washed twice in PBS. PBMC were 
then resuspended in RPMI/1% penicillin and streptomycin/1% L-glutamine and 
allowed to adhere for 30 minutes at 37°C on 96-well plates (.33x106 cells/well). 
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The cells were then washed two times with pre-warmed PBS, resuspended in 
RPMI/1% penicillin and streptomycin/1% L-glutamine/5% fetal bovine serum 
and allowed overnight at 37°C. 
8 
 
2.3 MP generation and purification 
PBMC were washed twice with PBS at 37°C. Upon addition of leptin for the 
indicated times, the supernatants were recovered, centrifuged at 14,000 x g for 
5 min at room temperature to remove dead cells and big cell fragments, and 
immediately used for further experiments. In some experiments, 12 mL of MP 
preparation were further purified by ultracentrifugation (100,000 x g for 2 hours, 
4°C); the resulting pellet was resuspended in normal saline (250 μL) and used 
for the detection of TF activity (see below). 
2.4 Measurement of MP 
PS-positive MP in each sample were detected using the Zymuphen MP-activity 
kit according to the manufacturer’s instructions and expressed as PS 
equivalents (nM PS). 
2.5 Flow cytometry detection of MP 
MP generated as described were analyze by flow cytometry. A mixture of 30 μL 
of supernatant, 3 μL of PE conjugated anti CD14 antibody, 3 μL of FITC labeled 
annexin V and 30 μL of annexin V 2x binding buffer was incubated for 15 
minutes at room temperature in the dark. Four-hundred μL of PBS were added 
to each mixture immediately before analysis with a FACScantotmII flow 
cytometer (BD Biosciences, San Jose, CA, USA).  Events acquisition was 
obtained at high flow rate and stopped after 210 seconds. The side scatter 
channel (SSc) and forward scatter channel (FSc) parameters were set at log 
scale. A PE conjugated mouse immunoglobulin G was used to confirm 
specificity of CD14 labeling. Monocyte-derived MP were discriminated first by 
size, as events conforming to a light scatter distribution within the .5-.9 μm bead 
range in a SSc vs. FSc window, as previously described [28], and further 
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identified as CD14+ and annexin V+ events in a PE vs. FITC window. In selected 
experiments, in addition to CD14-PE and annexin V-APC, CFSE was used to 
identify closed vesicles as CD14+ and CFSE+ events in PE vs. FITC windows. 
2.6 Measurement of intracellular calcium concentration 
The Molecular Probes Fluo-4 NW Calcium Assay kit was used to measure the 
changes in intracellular calcium concentration ([Ca2+]i) of PBMC. Pre-washed 
PBMC on 96-multiwell plate (.33 x 106 cells/well) were loaded with 100 μL of the 
dye loading solution containing Fluo-4 NW dye and probenecid, according to 
the manufacturer’s instructions. The 96-well plate was incubated at 37 °C for 
45-60 min in the dark and leptin (10 µg/mL) was added to the cells. The 
changes in Fluo-4 NW fluorescence were measured by the Wallac 1420 Victor 
2 (PerkinElmer, Milan, Italy) at λex 494 nm and λem 516 nm. Calcium 
mobilization was observed over time (up to 120 sec) and analyzed by the 
Wallac 1420 Software version 3 (PerkinElmer Life and Analytical Sciences, 
Wallac, Milan, Italy). The increase in [Ca2+]i fluorescence was expressed as 
relative fluorescence units (RFU). 
2.7 Assessment of MP-bound TF activity 
TF activity was measured in MP generated in vitro from PBMC by a one-stage 
clotting time assay exactly as described [29]. Briefly, MP (100 µl) disrupted by 3 
freeze-thaw cycles were mixed with an equal volume of MP-poor normal human 
plasma at 37°C; 25 mM CaCl2 (100 mL) was added to the mixture and the time 
to clot formation in a 37°C water bath was recorded. The results were 
expressed in arbitrary units (AU) of procoagulant activity by comparison with a 
standard curve obtained using a human brain thromboplastin standard. This 
preparation was assigned a value of 1,000 AU for a clotting time of 30 s. An 
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anti-human TF antibody (30 µg/mL) was used to confirm identity of the 
procoagulant activity with TF (data not shown). 
2.8 Assessment of apoptosis 
Apoptosis was measured using a commercially available kit as previously 
described [30]. Briefly, 10 x 106 cells/well were applied to six-well plates and 
treated as described above, cisplatin (30 μM) treatment was used as positive 
control.  After drug treatment, the PBMC were resuspended in 500 μl of binding 
buffer containing 5 μl of annexin V-FITC and 5 μl of propidium iodide-PE, and 
incubated in the dark at room temperature for 15 min. Cells were then analyzed 
in a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) to 
differentiate apoptotic cells (annexin V+ and propidium iodide-, lower right 
quadrant) from necrotic cells (annexin V+/propidium iodide+, upper right 
quadrant). Ten thousand events were recorded for each treatment group. 
2.9 Data presentation and statistical analysis 
Unless otherwise indicated, data are shown as mean + SEM from n (as stated 
in the relevant figure legend) independent consecutive experiments; 
comparisons among groups were made by either ANOVA for repeated 
measures followed by Bonferroni’s analysis or Student’s paired two-tailed t-test, 
as appropriate, using Prism Software (GraphPad, San Diego, CA, USA). Values 
of p < .05 were considered statistically significant. 
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3 Results 
3.1 Leptin induces MP generation by PBMC 
To investigate whether leptin induces the release of MP, PBMC were stimulated 
with 3 different concentrations of leptin at different time points; the supernatants 
were collected, and MP were quantified as PS concentration. The initial 
concentrations of leptin were selected based on previously published work by 
different groups [7, 8, 31]. As shown in figure 1, leptin stimulates the generation 
of MP by PBMC in a dose dependent fashion. The effect was maximum at 4 
hours and leveled off at later time points. 
 
 
figure 1. MP generation, expressed as PS concentration, by PBMC incubated with leptin. (A) 
Dose-response curve for leptin (4 h). (B) time-response curve for leptin (10 µg/mL). Data are 
from one experiment representative of 2. Open circles, baseline; closed cicles: leptin-stimulated 
cells. (C) MP generation by PBMC treated with leptin (4 h; 10 µg/mL). ***p<.001 for leptin 
treated cells compared with baseline (Student’s paired t-test); n=8 
 
To confirm the results and to investigate the cellular origin of these MP, flow 
cytometry was used. MP generation was expressed as events conforming to 
light scatter distribution within the .5-.9 µm bead range in a SSc vs FSc window 
and further identified as annexin V positive events and CD14 positive events. 
Figure 2 shows that leptin increases the number of annexin V+ MP (total MP) 
and of annexin V+/CD14+ MP (MP-derived MP). In selected experiments, we 
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also used CFSE to label MP in order to confirm that the events detected are 
closed vesicles with an intact membrane rather than cell debris [32]. CFSE+, i.e. 
intact, closed MP containing cytoplasm, represented the majority of events 
detected by flow cytometry (87.5% and 91.6% of total annexinV+/CD14+ events 
recorded within the appropriate physical gate in the experiments depicted in 
panels E and F, respectively). 
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Figure 2. Flow cytometric analysis of leptin-induced MP generation by PBMC. Cells were 
incubated in the absence (A, B and E) or in the presence (C, D and F) of leptin (10 µg/mL; 4 h). 
MP were analyzed by flow cytometry as described to identify all SSc
+
/annexin V
+
 events (A and 
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C), SSc
+
/CD14
+
 events (B and D), and CD14
+
/CFSE
+
 events (E and F). Representative data 
from one experiment.  (G) Statistical analysis of leptin-induced (10 µg/mL; 4 h) SSc
+
/annexin V
+
 
MP generation. (H) Statistical analysis of leptin-induced (10 µg/mL; 4 h) SSc
+
/CD14
+
 MP 
generation. **p<.01 for leptin treated cells compared with baseline (Student’s paired t-test); 
n=11.  
 
3.2 Leptin induces the expression of MP-bound TF by PBMC 
To evaluate whether leptin-induced MP express TF activity, a one-stage clotting 
test was used. As shown in figure 3, leptin induces an increase in MP-
associated procoagulant activity. A monoclonal antibody to TF (30 μg/mL) 
inhibited most of the procoagulant activity (not shown), confirming the identity of 
this activity with TF. 
 
 
Figure 3. Leptin induces the generation of TF bearing MP by PBMC. Cells were incubated with 
leptin (10µg/mL; 4 h).The supernatants were then tested for TF activity with a one-stage clotting 
assay. **p<.001 for leptin treated cells compared with baseline (Student’s paired t-test); n=3.  
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3.3 Leptin-induced MP generation is mediated by activation of extracellular 
signal regulated kinase (ERK) 1/2 but not by activation of c-Jun N-terminal 
kinase (JNK) and p38 
To investigate the implication of various proteins that compose the leptin 
intracellular pathway, we focused on mitogen activated protein kinases (MAPK). 
To this end, we used 3 different inhibitors of MAPK, an extracellular signal-
regulated kinase (ERK)1/2 inhibitor (PD98059), a c-JunN-terminal kinase (JNK) 
inhibitor (SP600125), and a p38 inhibitor (SB203580). Cells were pre-treated 
with PD98159 (1 µM), SP600125 (.65 µM) and SB203580 (1µM) for 30 minutes. 
All inhibitors were found non toxic by MTT assay [30]; furthermore, none caused 
MP release (data not shown). 
As shown in figure 4, only PD98159 inhibited MP generation by PBMC. 
 
 
Figure 4. MP generation, expressed as PS concentration, by PBMC incubated in the absence 
and in the presence of leptin (4 h; 10 µg/mL) and (A) PD98059 (1 µM; 30 minutes 
preincubation); (B) SB203580 (1 µM 30 minutes preincubation); (C) SP600125 (.65 µM; 30 
minutes preincubation). *p<.05 for leptin treated cells compared with baseline; ** p<.05 for 
leptin+PD98059 treated cells compared with leptin treated cells; NS: not significant (ANOVA 
analysis with Bonferroni post test); n=7. 
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3.4 Leptin induces the mobilization of intracellular calcium in PBMC 
Leptin has been shown to induce an increase in intracellular calcium 
concentration [33, 34]. Because calcium mobilization is involved in MP 
generation [11, 27, 28, 35], we investigated whether leptin increases [Ca2+]i in 
our experimental conditions. Figure 5 shows that leptin (10 µg/mL) induces a 
sustained increase in [Ca2+]i. 
 
 
Figure 5. Comparison of intracellular calcium concentration in PBMC in baseline conditions 
(open circles) and after leptin (10 μg/mL) treatment (solid circles), as assessed by Fluo4-NW 
incorporation (RFU: relative fluorescence units); n= 3. 
 
3.5 Leptin does not induce apoptosis is PBMC 
Besides calcium mediated cell activation, apoptosis is a well known mechanism 
of MP generation [11]. We investigated if in our experimental condition leptin 
induced MP generation through this mechanism. Figure 6 shows that leptin did 
not induce apoptosis. 
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Figure 6. Flow cytometry analysis of apoptosis of mononuclear cells. (A) PBMC cultured for 4 
hours in the absence of stimuli. (B) PBMC cultured for 4 hours in the presence of leptin (10 
μg/mL); (C) PBMC cultured for 20 hours in the absence of stimuli. (D) PBMC cultured for 20 
hours in the presence of cisplatin (12 μM) (positive control). Data from one experiment 
representative of two. 
 
3.6 Leptin-induced MP generation is mediated through phospholipase C (PLC) 
and calmodulin  
Numerous biological actions of leptin are mediated through calcium mobilization  
[33, 34]; furthermore, our data confirm that leptin causes an increase in [Ca2+]i 
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in PBMC in our experimental conditions. We therefore set up to investigate the 
role of some of the molecular pathways involved in calcium signaling in MP 
generation. We used a PLC inhibitor, U73122, to investigate the role of calcium 
ions stored in the endoplasmic reticulum. Cells were pre-treated with U73122 (1 
µM) for 30 minutes. To look into how calcium ions may act after their release we 
used a calmodulin inhibitor, W-7 (.650 µM for 30 minutes). Both inhibitors were 
found non toxic by MTT assay [30]; furthermore, neither caused MP release 
(data not shown). 
Cell treatment with both U73122 (fig. 7) and W-7 (fig. 8) inhibited MP production 
induced by leptin 
 
 
Figure 7. MP generation, expressed as PS concentration, by PBMC incubated in the absence 
and in the presence of leptin (4 h; 10 µg/mL) and U73122 (1 µM; 30 minute pretreatment). 
*p<.05 for leptin treated cells compared with baseline; ** p<.05 for leptin+U73122 treated cells 
compared with leptin treated cells (ANOVA analysis with Bonferroni post test); n=7. 
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Figure 8. MP generation, expressed as PS concentration, by PBMC incubated in the absence 
and in the presence of leptin (4 h; 10 µg/mL) and W-7 (.65 µM; 30 min pretreatment). *p<.01 for 
leptin treated cells compared with baseline; ** p<.05 for leptin+W-7 treated cells compared with 
leptin treated cells (ANOVA analysis with Bonferroni post test); n=8. 
 
Inhibition of leptin-induced MP generation by PD98059, U73122 and W-7 was 
confirmed by flow cytometry (fig. 9). 
 
Figure 9. Flow cytometry analysis of the inhibitory effects of PD98059, U73122, and W-7 in 
leptin-induced MP generation by human mononuclear cells; n=3. MP were analyzed as 
described in figure 2. Experimental conditions were identical to those described in figure 4, 7 
and 8. 
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4 Discussion 
The aim of this work was to test the hypothesis that leptin induces the 
generation of procoagulant MP. Indeed, we show that leptin causes the release 
of procoagulant MP by PBMC in a dose- and time-dependent fashion; flow 
cytometric analysis identified a portion of these MP as of monocytic origin. 
Although linear membrane fragments can be generated upon cell manipulation 
and stimulation, we confirmed that the vast majority of PS generated in our 
experimental conditions was associated to microparticles. Because MP of 
monocytic origin may express TF [19], which adds to their procoagulant 
potential, we also investigated the presence of TF activity on leptin-stimulated 
PBMC-derived MP, and confirmed the presence of functionally active TF on the 
surface of leptin-induced MP. Freeze-thaw cycles have been proposed as a 
suitable way to externalize PS and decrypt TF on intact cells prior to functional 
analysis with clotting assays [36]. This step is probably irrelevant with MP and in 
fact Lee and Mackman have shown that, contrary to what anticipated, 
freeze/thaw has no effect on MP-bound TF [37]. However, we have chosen to 
perform the standard freeze/thaw cycles for consistency with our previous work 
[27-29, 35, 38]. PBMC, like other cell types, generate MP upon stimulation with 
various stimuli, including bacterial lipopolysaccharide [39], the calcium 
ionophore A23187 [40], angiotensin II [35], peroxisome proliferator activated 
receptor-γ agonists [29], cigarette smoke extract [28, 41]. The role of leptin in 
TF regulation has been previously extensively analyzed [8, 10]. Therefore, our 
experimental design was not devised to investigate the mechanisms of leptin-
induced TF synthesis. In contrast, because different stimuli induce generation of 
TF-bearing MP with different mechanisms, we investigated the specific 
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mechanism(s) whereby leptin induces MP generation in our experimental 
conditions. Cell activation and apoptosis can cause MP generation [11]. 
Proteins of the MAPK family are involved in both cell activation and apoptosis 
[42] and act in the intracellular leptin pathway [43]. We therefore investigated 
the role of the members of the MAPK family, ERK1/2, JNK and p38, on leptin-
induced MP release by PBMC. We found that only an ERK1/2 inhibitor, 
PD98059, decreases MP generation. This observation led us to conclude that 
leptin-induced MP generation is mediated by the activation of ERK1/2. This 
conclusion is consistent with the previous observation that ERK1/2 is 
phosphorylated by leptin stimulation in human PBMC [44].  
The relatively short time-frame of MP generation upon stimulation with leptin, as 
well as the observation that this phenomenon is not affected by inhibition of JNK 
and p38, members of the MAPK family mostly involved in apoptotic phenomena 
[45], suggests cell activation, rather than apoptosis, as the relevant mechanism. 
A critical step in the process that leads to cell activation, and eventually to MP 
release, is an increase in [Ca++]i [11, 29]. The observation that leptin induces 
calcium mobilization led us to conclude that the release of MP by PBMC takes 
place through cell activation. The observation that the number of apoptotic cells, 
as assessed by annexin-V/propidium iodide binding, is not affected by leptin 
treatment in our experimental conditions is in agreement with this conclusion. 
Based on the known role of PLC in the intracellular signaling pathways 
activated by leptin [43, 46], we postulated a role for this protein on leptin-
induced MP generation. The observation that pretreatment with the PLC 
inhibitor, U73122, significantly downregulates MP generation is consistent with 
the hypothesis that MP shedding requires calcium mobilization from intracellular 
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storage pools that takes place via phosphatidylinositol (3,4,5) trisphosphate  
[43].  
Calmodulin, a small protein of 148 aminoacids, functions as a sensor that 
couples Ca2+ signals to biochemical and cellular changes and represents the 
most abundant Ca2+ sensor in non muscle cells. Calmodulin participates in the 
regulation of the Ras signaling pathways, leading to MAPK activation [47]. Our 
observation that calmodulin inhibition with W-7 reduces MP generation confirms 
a role for this protein as a Ca2+ sensor in leptin-induced MP generation by 
PBMC. 
In conclusion, our data demonstrate that leptin induces the generation of 
procoagulant, TF-bearing MP by PBMC through a mechanism involving calcium 
mobilization by PLC and the calmodulin-mediated activation of the MAPK-
ERK1/2 pathway. 
Procoagulant MP likely contribute to the increased atherothrombotic risk in 
obese patients. Pharmacological modulation of MP generation, for example 
through the inhibition of ERK1/2 and/or of calcium mobilization, or calmodulin 
mediated signaling, might prove helpful in preventing such events. Although 
great care must be taken when inferring in vivo relevance from data generated 
in vitro, the recent observation that during weight loss leptin plasma levels 
decrease in parallel with procoagulant platelet- , leukocyte-, and endothelial 
cell-derived MP [48, 49] lends support to the physiologic relevance of our data. 
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Legend to the figures 
 
Figure 1. MP generation, expressed as PS concentration, by PBMC incubated 
with leptin. (A) Dose-response curve for leptin (4 h). (B) time-response curve for 
leptin (10 μg/mL). Data are from one experiment representative of 2. (C) MP 
generation by PBMC treated with leptin (4 h; 10 μg/mL). ***p<0.001 for leptin 
treated cells compared with baseline (Student’s paired t-test); n=8 
 
Figure 2. Flow cytometric analysis of leptin-induced MP generation by PBMC. 
Cells were incubated in the absence (A, B and E) or in the presence (C, D and 
F) of leptin (10 µg/mL; 4 h). MP were analyzed by flow cytometry as described 
to identify all SSc+/annexin V+ events (A and C), SSc+/CD14+ events (B and D), 
and CD14+/CFSE+ events (E and F). Representative data from one experiment.  
(G) Statistical analysis of leptin-induced (10 µg/mL; 4 h) SSc+/annexin V+ MP 
generation. (H) Statistical analysis of leptin-induced (10 µg/mL; 4 h) 
SSc+/CD14+ MP generation. **p<.01 for leptin treated cells compared with 
baseline (Student’s paired t-test); n=11.  
 
Figure 3. Leptin induces the generation of TF bearing MP by PBMC. Cells were 
incubated with leptin (10μg/mL; 4 h).The supernatants were then tested for TF 
activity with a one-stage clotting assay. ***p<.001 for leptin treated cells 
treated cells compared with baseline (Student’s paired t-test); n=3.  
 
Figure 4. MP generation, expressed as PS concentration, by PBMC incubated 
in the absence and in the presence of leptin (4 h; 10 µg/mL) and (A) PD98059 
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(1 µM; 30 minutes preincubation); (B) SB203580 (1 µM 30 minutes 
preincubation); (C) SP600125 (.65 µM; 30 minutes preincubation). *p<.05 for 
leptin treated cells compared with baseline; ** p<.05 for leptin+PD98059 treated 
cells compared with leptin treated cells; NS: not significant (ANOVA analysis 
with Bonferroni post test); n=7. 
 
Figure 5. Comparison of intracellular calcium concentration in PBMC in baseline 
conditions (open circles) and after leptin (10 μ /mL) treatment (solid circles), as 
assessed by Fluo4-NW incorporation (RFU: relative fluorescence units); n= 3. 
 
Figure 6. Flow cytometry analysis of apoptosis of mononuclear cells. (A) PBMC 
cultured for 4 hours in the absence of stimuli. (B) PBMC cultured for 4 hours in 
the presence of leptin (10 μg/mL); (C) PBMC cultured for 20 hours in the 
absence of stimuli. (D) PBMC cultured for 20 hours in the presence of cisplatin 
(12 μM) (positive control). Data from one experiment representative of two. 
 
Figure 7. MP generation, expressed as PS concentration, by PBMC incubated 
in the absence and in the presence of leptin (4 h; 10 μg/mL) and U73122 (1 μM; 
30 minute pretreatment). *p<.05 for leptin treated cells compared with baseline; 
** p<.05 for leptin+U73122 treated cells compared with leptin treated cells 
(ANOVA analysis with Bonferroni post test); n=7. 
 
Figure 8. MP generation, expressed as PS concentration, by PBMC incubated 
in the absence and in the presence of leptin (4 h; 10 μg/mL) and W-7 (0.65 μM; 
30 min pretreatment). *p<.01 for leptin treated cells compared with baseline; ** 
p<.05 for leptin+W-7 treated cells compared with leptin treated cells (ANOVA 
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analysis with Bonferroni post test); n=8. 
 
Figure 9. Flow cytometry analysis of the inhibitory effects of PD98059, U73122, 
and W-7 in leptin-induced MP generation by human mononuclear cells; n=3. 
MP were analyzed as described in figure 2. Experimental conditions were 
identical to those described in figure 4, 7 and 8. 
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